See why we're the #1 CGM in the US*.

The FreeStyle Libre 2 system includes the Libre 2 Plus sensor, Libre 2 sensor, Libre app, and the Libre 2 reader.

The FreeStyle Libre 3 system includes the Libre 3 Plus sensor, Libre 3 sensor, Libre app, and the Libre 3 reader.

FreeStyle Libre 3 and FreeStyle Libre 2 systems are indicated for use in people with diabetes ages 4 and older.

Freestyle Libre 2 Plus sensor and 3 Plus sensor are indicated for use in people with diabetes age 2 and older.

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

* Based on retail and durable medical equipment (DME) sales data for patient’s last-filled prescription, by manufacturer.

† Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.

‡ 60-minute warm-up required when starting the sensor.

§ Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2) or 33 feet (FreeStyle Libre 3) unobstructed of the reading device.

|| The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.

¶ Not made with these skin allergens. IBOA and MBPA not detected. Test method limit of detection was 0.0016 μg per device for IBOA and 0.0079 μg per device for MBPA.

# Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre personal CGM systems require a prescription.

♢ Eligible patients will receive one (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 diabetes or Type 2 diabetes or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor. Patients ages 4–17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. Patients ages 2–17 are eligible to receive an offer for the (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 system sensor or FreeStyle Libre 3 system sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

References: 1. FreeStyle Libre 2 User’s Manual. 2. FreeStyle Libre 3 User’s Manual. 3. Data on file. Abbott Diabetes Care, Inc. 4. Alva, Shridhara, et al. "Accuracy of the Third Generation of a 14-day Continuous Glucose Monitoring System." Diabetes Therapy 14, no. 4 (2023): 767–776. https://doi.org/10.1007/s13300-023-01385-6. 5. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 6. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People With Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294–1301. https://doi.org/10.1111/pedi.12735. 7. Based on FSL2 and FSL3 User Manuals, Dexcom G7 CGM User Guide, and Medtronic Guardian Connect System User Guide. 8. Dexcom G7 CGM User Guide. 9. Mowitz, Martin, et al. “New Device, ‘Old’ Allergens. Allergic Contact Dermatitis Caused by the Dexcom G7 Glucose Sensor.” Contact Dermatitis 90, no. 5 (2024): 495–500. https://doi.org/10.1111/cod.14514.

ADC-36559 v5.0